Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
16 Octubre 2023 - 7:56AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced today that clinical findings from
the NeuroStar Outcomes Registry are published in the premier
journal in the field of neuromodulation, Brain Stimulation: Basic,
Translational, and Clinical Research in Neuromodulation. The data
reveal a robust association between the number of treatment
sessions received and improved depression outcomes, providing
actionable evidence for clinicians prescribing transcranial
magnetic stimulation (TMS) therapy to treat major depressive
disorder (MDD).
Findings from this study of over 7,000 patients demonstrate that
patients who received a full course of 36 TMS sessions had an 82%
greater improvement in remission rate and a 43% greater improvement
in response rate compared to patients who ended their TMS course
with fewer than 30 sessions. Historically, TMS therapy is
discontinued by either the patient or the practitioner at various
points of treatment, but the findings published in Brain
Stimulation demonstrate that stopping treatment before 36 sessions
is associated with significantly reduced treatment
effectiveness.
“These findings underscore the importance of patients completing
the full prescribed treatment course to achieve the best outcomes,”
stated Cory Anderson, SVP of R&D and Clinical. “NeuroStar
providers can improve treatment adherence and support for patients
by using our proprietary TrakStar platform to deliver regular
touchpoints and support messages to patients. Customers who use
these proprietary TrakStar features demonstrated a 20% increase in
the number of patients completing all 36 treatments.”1
In addition to the significant dose response for a majority of
patients, the analysis from the study also revealed that some
patients who have a slower initial response may benefit from
extended treatment beyond 36 treatments.
"As ample evidence suggests, the therapeutic effects of
antidepressant medications often reach a plateau, regardless of
increased dosage or extended duration,” said Dr. Harold Sackeim,
Professor in Psychiatry and Radiology at Columbia University. “In
addition to showing that TMS patients who completed the entire
36-session treatment achieved the most significant reduction in
PHQ-9 scores, the findings from the study also demonstrate
substantial benefit for patients who needed extended treatment.
Notably, there was no plateau in antidepressant response in any TMS
group. The NeuroStar Outcomes Registry is providing a wealth of
data on real-world outcomes, and substantially shaping our
understanding of clinical best practices for TMS therapy in
MDD.”
The NeuroStar Outcomes Registry is the world’s largest registry
of depression outcomes. Via the company’s proprietary TrakStar
management system, it collects real-world treatment data with the
use of NeuroStar Advanced Therapy, a non-invasive and FDA-cleared
treatment for depression and other mental health conditions. For
more information about NeuroStar TMS Therapy, please visit
NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.6 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
______________________________1 Data on file. Neuronetics,
Inc.
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024